Video

Immunotherapy Combination Strategies in RCC

For High-Definition, Click

Immunotherapy combination strategies in renal cell carcinoma could be hampered by toxicity concerns, believes Brian I. Rini, MD. The need for combination approaches with a PD-1 inhibitor and a CTLA-4 inhibitor should be personalized based on patient characteristics. However, deciding which patient should receive a combination versus a single-agent remains to be seen.

Related Videos
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Astrocytoma
December 2nd 2024

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
May 2nd 2022

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health
November 27th 2024

Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression

Manali I. Patel, MD, MPH, MS, of Stanford University School of Medicine
November 26th 2024

Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans